In case you missed it: August 16 to August 20
It was a busy week for the Contemporary OB/GYN team.
This week's top articles included:
FDA accepts pembrolizumab as single agent for treatment of advanced endometrial cancer
The FDA has accepted a new supplemental biologics license application for pembrolizumab, an anti-PD-1 therapy, as a single agent for the treatment of patients with advanced endometrial carcinoma that is microsatellite instability-high or mismatch repair deficient, who have diseased progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.
New biomarker could predict immunotherapy benefit in breast cancer
The Major Histocompatibility Complex Class II protein has potential to predict immunotherapy benefit in two types of breast cancer.
Hormonal intravaginal rings could facilitate combination therapies for several conditions
“Topical drug delivery also provides higher concentrations of the drug to the target site and has fewer side effects,” wrote the authors.
New Hampshire's abortion restrictions
We spoke with Editorial Board member Ilana Cass, MD, about her opinion of her state's latest abortion restrictions.
Balancing VTE and bleeding risks in gynecologic cancer surgeries
December 6th 2024A comprehensive analysis shows the benefits of thromboprophylaxis often outweigh the bleeding risks during gynecologic cancer procedures, though patient-specific risk factors are crucial for decision-making.
Read More
Expert consensus sheds light on diagnosis and management of vasa previa
December 5th 2024A recent review established guidelines for prenatal diagnosis and care of vasa previa, outlining its definition, screening and diagnosis, management, and timing of delivery in asymptomatic patients.
Read More
